Compare · CDXS vs DNA
CDXS vs DNA
Side-by-side comparison of Codexis Inc. (CDXS) and Ginkgo Bioworks Holdings Inc. (DNA): market cap, price performance, sector, and recent activity on the wire.
Summary
- CDXS operates in Industrials, while DNA operates in Health Care - the two are in different parts of the market.
- DNA is the larger of the two at $623.0M, about 4.9x CDXS ($126.9M).
- CDXS has been more active in the news (9 items in the past 4 weeks vs 8 for DNA).
- DNA has more recent analyst coverage (18 ratings vs 12 for CDXS).
- Company
- Codexis Inc.
- Ginkgo Bioworks Holdings Inc.
- Price
- -
- -
- Market cap
- $126.9M
- $623.0M
- 1M return
- -
- -
- 1Y return
- -
- -
- Industry
- Major Chemicals
- Biotechnology: Biological Products (No Diagnostic Substances)
- Exchange
- NASDAQ
- NYSE
- IPO
- 2010
- 2021
- News (4w)
- 9
- 8
- Recent ratings
- 12
- 18
Codexis Inc.
Codexis, Inc. discovers, develops, and sells biocatalysts. It offers intermediate chemicals products that are used for further chemical processing; and Codex biocatalyst panels and kits that enable customers to perform chemistry screening. The company also provides biocatalyst screening and protein engineering services. In addition, it offers CodeEvolver protein engineering technology platform, which helps in developing and delivering biocatalysts that perform chemical transformations. The company's platform is used to discover novel biotherapeutic drug candidates for targeted human diseases, as well as for molecular biology and in vitro diagnostic enzymes. Its platform also enhances the pharmaceuticals companies manufacturing productivity and efficiency or outsourcing the manufacture of the intermediates and active pharmaceutical ingredients. The company sells its products to pharmaceutical manufacturers through its direct sales and business development force in the United States and Europe. Codexis, Inc. was founded in 2002 and is headquartered in Redwood City, California.
Ginkgo Bioworks Holdings Inc.
Ginkgo Bioworks Holdings, Inc. develops platform for cell programming. Its platform is used to program cells to enable biological production of products, such as novel therapeutics, food ingredients, and chemicals derived from petroleum. The company serves various end markets, including specialty chemicals, agriculture, food, consumer products, and pharmaceuticals. Ginkgo Bioworks Holdings, Inc. was founded in 2008 and is based in Boston, Massachusetts.
Latest CDXS
- SEC Form 10-Q filed by Codexis Inc.
- Codexis Inc. filed SEC Form 8-K: Results of Operations and Financial Condition, Financial Statements and Exhibits
- Codexis Reports Third Quarter 2026 Financial Results and Provides Business Update
- Director De Vre Raymond sold $1,208 worth of shares (1,088 units at $1.11), decreasing direct ownership by 1% to 83,723 units (SEC Form 4)
- Codexis Inc. filed SEC Form 8-K: Entry into a Material Definitive Agreement, Termination of a Material Definitive Agreement, Creation of a Direct Financial Obligation, Unregistered Sales of Equity Securities, Financial Statements and Exhibits
- Codexis Enters into $60 Million Term Loan Facility with Trinity Capital
- Codexis Advances ECO Synthesis Toward Adoption Readiness with Quality at Scale and Expanded siRNA Manufacturing Capabilities
- Amendment: SEC Form SCHEDULE 13G/A filed by Codexis Inc.
- Codexis to Report Third Quarter 2026 Financial Results on November 12
- Officer Erbez Georgia sold $8,619 worth of shares (6,335 units at $1.36) (SEC Form 4)
Latest DNA
- SEC Form 10-Q filed by Ginkgo Bioworks Holdings Inc.
- Ginkgo Bioworks Holdings Inc. filed SEC Form 8-K: Results of Operations and Financial Condition, Financial Statements and Exhibits
- Ginkgo Bioworks Reports Third Quarter 2026 Results; Signs First Autonomous Lab Sale to a Top-Tier Pharma Company Novo
- SEC Form 8-K filed by Ginkgo Bioworks Holdings Inc.
- Officer Coen Steven P. sold $7,770 worth of shares (766 units at $10.14) (SEC Form 4)
- Officer Shetty Reshma P. sold $417,608 worth of shares (41,172 units at $10.14) (SEC Form 4)
- Large owner Canton Barry sold $417,608 worth of shares (41,172 units at $10.14) (SEC Form 4)
- Officer Kelly Jason R sold $463,353 worth of shares (45,682 units at $10.14) (SEC Form 4)
- Ginkgo Bioworks to Provide Autonomous Lab Access to NSF X-Labs Researchers, Contributing Cloud Lab Time and Protein Testing Services to $1.5 Billion Breakthrough Science Program
- Araceli Biosciences and Ginkgo Bioworks Bring Cellular Imaging at Scale to Nebula's Lab-in-the-Loop